Last reviewed · How we verify
Recombinant Herpes Zoster Vaccine
Recombinant Herpes Zoster Vaccine is a vaccine Biologic drug developed by Beijing Luzhu Biotechnology Co., Ltd.. It is currently in Phase 3 development for Prevention of shingles in adults aged 50 years and older. Also known as: LZ901.
The recombinant Herpes Zoster Vaccine works by stimulating the body's immune system to produce a specific response against the Herpes Zoster virus.
The recombinant Herpes Zoster Vaccine works by stimulating the body's immune system to produce a specific response against the Herpes Zoster virus. Used for Prevention of shingles in adults aged 50 years and older.
At a glance
| Generic name | Recombinant Herpes Zoster Vaccine |
|---|---|
| Also known as | LZ901 |
| Sponsor | Beijing Luzhu Biotechnology Co., Ltd. |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains a weakened form of the virus, which triggers an immune response without causing the disease. The immune system then produces antibodies and immune cells that can recognize and fight the virus, providing long-term protection against shingles.
Approved indications
- Prevention of shingles in adults aged 50 years and older
Common side effects
- Pain, redness, swelling, or itching at the injection site
Key clinical trials
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients (PHASE4)
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) (PHASE3)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
- Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation (PHASE2)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Herpes Zoster Vaccine CI brief — competitive landscape report
- Recombinant Herpes Zoster Vaccine updates RSS · CI watch RSS
- Beijing Luzhu Biotechnology Co., Ltd. portfolio CI
Frequently asked questions about Recombinant Herpes Zoster Vaccine
What is Recombinant Herpes Zoster Vaccine?
How does Recombinant Herpes Zoster Vaccine work?
What is Recombinant Herpes Zoster Vaccine used for?
Who makes Recombinant Herpes Zoster Vaccine?
Is Recombinant Herpes Zoster Vaccine also known as anything else?
What drug class is Recombinant Herpes Zoster Vaccine in?
What development phase is Recombinant Herpes Zoster Vaccine in?
What are the side effects of Recombinant Herpes Zoster Vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: Beijing Luzhu Biotechnology Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of shingles in adults aged 50 years and older
- Also known as: LZ901
- Compare: Recombinant Herpes Zoster Vaccine vs similar drugs
- Pricing: Recombinant Herpes Zoster Vaccine cost, discount & access